Mumbai, February 10, 2018: Pharma Major Alkem Laboratories has inked an out-licensing deal with Stempeutics Research, a group company of Manipal Education and Medical Group (MEMG), for Stempeucel merchandise For gout sign.
The outside licensing deal comprises of upfront payment, royalties and respective regulatory & sales based landmarks payments.
Under this agreement, Alkem will get the exclusive marketing rights for Stempeucel in India for Osteoarthritis with Stempeutics manufacturing and supplying the product to Alkem.
The product is expected to be available in Indian market by 2020 after undergoing the stage 3 Clinical trial in India, which is anticipated to commence in 2018.
New Delhi, May 17, 2024: In response to the growing need for specialized pediatric care,…
Achieves significant advancement in Cancer Treatment to Enhance Quality of Life As per the National…
-An 11-year-old boy from Yemen and a 34-year-old man from Bengaluru, both suffered from end-stage…
Mumbai, 14th May 2024 – As part of its dedication to exceptional patient care, American Oncology…
Mumbai, May 11, 2024: In a landmark move for Indian healthcare, the introduction of Second…
Bengaluru, May 08, 2024: Cancer remains the illness most feared across the globe. But to combat…